newsfilter
← Latest News
Business Wire·

Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

IVERIC bio, Inc. (NASDAQ:ISEE) announced today a post-hoc analysis from the Zimura® (avacincaptad pegol) GATHER1 clinical trial which explored enhanced Optical Coherence Tomography (OCT) image analysis to examine the effect of Zimura on change in Ellip